Source: The Insides Company Limited
On: Wednesday 19 August 2020 – Auckland
Companies: The Insides Company Limited
The Insides Company’s premier chyme reinfusion device, The Insides™ Systemfi, has been selected by researchers at the University of Auckland for a pivotal clinical trial.
For patients with temporary ileostomies, fluid and nutrient loss is a serious side effect. The Insides Company has invented a novel device to recycle these contents to the patient and prevent many of the associated complications.
Researchers at the University of Auckland have been awarded a grant from the Health Research Council of New Zealand in the amount of $1.4 million. This grant will fund a randomised controlled trial of this medical device. This study is currently enrolling participants at Auckland City Hospital and is expected to run for 3 years.